Ignite Creation Date:
2025-12-24 @ 3:29 PM
Ignite Modification Date:
2026-02-20 @ 10:44 PM
Study NCT ID:
NCT05652192
Status:
RECRUITING
Last Update Posted:
2022-12-15
First Post:
2022-11-08
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
SBRT Combined With Chemotherapy and Tislelizumab in Metastatic NPC
Sponsor:
Zhejiang Cancer Hospital
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
IRB-2022-514
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None